Establishment of lapatinib-resistant breast cancer and preliminary study on the resistance-reversing function of metformin
返回论文页
|更新时间:2023-12-22
|
Establishment of lapatinib-resistant breast cancer and preliminary study on the resistance-reversing function of metformin
Journal of Chongqing Medical UniversityVol. 43, Issue 8, Pages: 1097(2018)
作者机构:
1. 重庆医科大学基础医学院病理生理学教研室,重庆,400016
2. 重庆医科大学附属第二医院三腺外科,重庆,400010
作者简介:
基金信息:
DOI:
CLC:
Published:2018,
扫 描 看 全 文
Wang Ting, Chen Peng, Xu Ting, et al. Establishment of lapatinib-resistant breast cancer and preliminary study on the resistance-reversing function of metformin. [J]. Journal of Chongqing Medical University 43(8):1097(2018)
DOI:
Wang Ting, Chen Peng, Xu Ting, et al. Establishment of lapatinib-resistant breast cancer and preliminary study on the resistance-reversing function of metformin. [J]. Journal of Chongqing Medical University 43(8):1097(2018)DOI:
Establishment of lapatinib-resistant breast cancer and preliminary study on the resistance-reversing function of metformin
Objective:To establish a model of lapatinib-resistance in breast cancer and explore the reversal effect of metformin on the resistance. Methods:The model of lapatinib-resistance in breast cancer was established in vitro. The experiment cells were divided into the parent group,blank resistance group,lapatinib group,metformin group and lapatinib-metformin group(n=3). CCK-8 method was used to detect and calculate the resistance times of blank resistance group and the resistance-reversing times of metformin group. The apoptosis rate and cycle of each group were detected by FCM,and the expressions of proteins related to PI3K signaling pathway in each group by Western blot. Results:The sensitivity of cells to lapatinib in blank resistance group was lowered. IC50 values in the parent group,blank resistance group,and metformin group were (2.64±0.12),(11.21±0.03),and (5.62±0.13) μmol/L respectively. The drug resistance was about 4.25 and the reversal of drug resistance was approximately 2.0. Compared with the blank resistance group,the cell proliferation index significantly decreased in both metformin group(0.73±0.04 vs. 1.11±0.02)(P=0.004) and the lapatinib-metformin group(0.63±0.06 vs. 1.11±0.02)(P=0.031),while the cell apoptosis rate significantly increased in both metformin group([(10.70±0.76)%] vs. [(5.05±0.59)%])(P=0.007)and the lapatinib-metformin group([(24.68±1.52)%] vs. [(5.05±0.59)%])(P=0.006). The expressions of PI3K signaling pathway-associated phosphorylated and non-phosphorylated proteins in lapatinib-metformin group were lower than those in the blank resistance group. Conclusion:The lapatinib-resistant model of breast cancer has been successfully established. Metformin can reverse the drug resistance of lapatinib in breast cancer cell by inhibiting the PI3K signaling pathway.
关键词
乳腺癌二甲双胍拉帕替尼逆转耐药PI3K信号通路
Keywords
breast cancermetforminlapatinibreversal resist-ancePI3K signaling pathway
Pathomics signature based on machine learning can predict the response to neoadjuvant chemotherapy in breast cancer patients
Comparison of remission of metformin,pioglitazone and their combination on early abnormal glucose metabolism in patients with polycystic ovary syndrome
Effects of circular RNA hsa_circ_0002185 on cell viability and invasion of breast cancer cells and its mechanism of action
Prediction and identification of H-2Kd restricted CTL epitope derived from breast cancer associated antigen ROR1
Comparison of lung dosimetry between supine and sternal horizon positions during X-ray irradiated radical mastectomy radiation therapy
Related Author
Zhang Jieqiu
Wu Qi
Wang Jianmei
Yao Xiaopeng
Liu Qicong
Liu Qing
Yao Huodi
Liu Dongfang
Related Institution
Department of Epidemiology and Health Statistics, School of Public Health,Southwest Medical University
Department of Pathology,The Affiliated Hospital of Southwest Medical University
Department of Medical Engineering Technology,School of Medical Information and Engineering,Southwest Medical University
Endocrinology and Metabolism Department,The Second Affiliated Hospital of Chongqing Medical University
Oncological Surgery Third Department, General Hospital of Ningxia Medical University